Fed and fasted bioequivalence assessment of two formulations of extended-release fixed-dose combination dapagliflozin/metformin (10/1,000 mg) tablets in healthy subjects

Two open-label, randomized, two-period crossover studies were conducted to investigate the pharmacokinetic (PK) properties, safety, and bioequivalence of the test formulation (KD4004), a new fixed-dose combination (FDC) formulation of dapagliflozin and metformin extended release (XR) tablets, relati...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Hae Won, Kang, Woo Youl, Park, Ji Seo, Lee, Jae Hwa, Gwon, Mi-Ri, Yang, Dong Heon, Kim, Eun Hee, Park, Soo-Jin, Yoon, Young-Ran, Seong, Sook Jin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean Society for Clinical Pharmacology and Therapeutics 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10333646/
https://www.ncbi.nlm.nih.gov/pubmed/37440782
http://dx.doi.org/10.12793/tcp.2023.31.e10

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10333646/
https://www.ncbi.nlm.nih.gov/pubmed/37440782
http://dx.doi.org/10.12793/tcp.2023.31.e10

Ejemplares similares